Personal CFO Solutions LLC Has $860,000 Stake in Medtronic PLC $MDT

Personal CFO Solutions LLC reduced its position in shares of Medtronic PLC (NYSE:MDT) by 15.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,867 shares of the medical technology company’s stock after selling 1,747 shares during the period. Personal CFO Solutions LLC’s holdings in Medtronic were worth $860,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Legacy Advisory Services LLC acquired a new stake in shares of Medtronic during the 1st quarter worth about $541,000. GC Wealth Management RIA LLC raised its holdings in Medtronic by 20.6% in the 2nd quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock valued at $2,926,000 after acquiring an additional 5,734 shares during the period. Verdence Capital Advisors LLC lifted its position in Medtronic by 22.0% during the second quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after acquiring an additional 5,296 shares during the last quarter. World Investment Advisors boosted its holdings in shares of Medtronic by 1.9% during the second quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock worth $13,608,000 after acquiring an additional 2,868 shares during the period. Finally, Sivik Global Healthcare LLC grew its position in shares of Medtronic by 6.7% in the second quarter. Sivik Global Healthcare LLC now owns 80,000 shares of the medical technology company’s stock valued at $6,974,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on MDT shares. Wells Fargo & Company lifted their price target on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday. Truist Financial lifted their target price on Medtronic from $103.00 to $110.00 and gave the stock a “hold” rating in a report on Thursday. Royal Bank Of Canada upped their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday. Leerink Partners set a $120.00 price objective on shares of Medtronic and gave the stock an “outperform” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $109.72.

Medtronic Stock Up 1.8%

MDT stock opened at $101.16 on Friday. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $102.59. The business has a 50-day simple moving average of $95.04 and a 200 day simple moving average of $90.88. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The company has a market cap of $129.76 billion, a PE ratio of 27.87, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.